Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Theorem Clinical Research, Charles River Form Strategic Alliance

Published: Monday, September 23, 2013
Last Updated: Sunday, September 22, 2013
Bookmark and Share
New alliance provides nonclinical testing programs.

Theorem Clinical Research has announced the formation of a strategic alliance with Charles River Laboratories that will provide clients with an integrated solution from nonclinical testing and analysis through clinical development and registration.

The new alliance provides nonclinical testing programs in the areas of bioanalysis, immunogenicity and immunology to support clinical trials.

“Charles River develops and validates assays in support of nonclinical programs, and many of these assays can be validated for human matrix and used for analyzing clinical samples,” said Dr. Marc Hoffman, Theorem senior vice president and general manager of biopharmaceutical development.

Charles River’s high-quality research models, preclinical testing capabilities and clinical support services are backed by a comprehensive bioanalysis portfolio for non-GLP and GLP programs.

Laboratories are equipped with the latest instrumentation to measure drug and metabolite concentrations in biological matrices and to provide full support for capillary micro sampling and dried blood spot analysis.

The variety of advanced equipment ensures the capacity to meet critical deadlines.

“We are pleased to partner with a world-class clinical trials organization like Theorem Clinical Research. Sponsors will benefit from the experience of both organizations. The alliance will offer a seamless transition from preclinical testing into the clinical arena,” said Alan Bartlett, executive director of laboratory services, Charles River Laboratories.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Theorem Clinical Research Expands Leadership and Prepares for Growth
Addition of Kathryn Bohannon as vice president of biopharmaceutical development and Angela Weston as vice president business development.
Thursday, November 13, 2014
Ximedica Joins Theorem Clinical Research Strategic Alliance Group
Will work to design medical solutions that meet a range of safety requirements.
Thursday, September 12, 2013
Theorem Adds RadMD to its Roster of Strategic Alliances
Expands imaging capabilities.
Friday, August 16, 2013
Theorem Clinical Research Distributes Clinical Trial Advice
Company releases booklets to provide ICH GCP guidance for in vitro and investigational product trials.
Thursday, February 28, 2013
Theorem and Gallus Announce an Exclusive Partnership
Partnership to help companies accelerate their research, development and manufacturing of biopharmaceuticals.
Monday, August 13, 2012
Theorem Clinical Research Appoints Vice President of Global Regulatory Affairs
The CRO has announced the appointment of food and drug law expert Brian Bollwage, J.D., as Vice President of Global Regulatory Affairs.
Wednesday, January 18, 2012
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!